Follicular lymphoma (a chronic disease process) transforms to DLBCL (an acute disease process). This site needs JavaScript to work properly. doi: 10.1038/sj.bjc.6602297, 40. Figure S3. Only one health economic study was identified – a US study using data from 2006-2009 which estimated the cost of disease progression. 2015 Jun 1;121(11):1800-8. doi: 10.1002/cncr.29290. Moreover, the 5-year survival rates have improved dramatically from the 1970s to 2010s (44.15 vs. 63.7%), and the most obvious increase occurred in patients with primary site in the head/neck. National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error. Get the latest research from NIH: https://www.nih.gov/coronavirus. doi: 10.1038/s41564-018-0334-0, 43. The prognostic signature for 1-, 5-, and 10-year overall survival is demonstrated in Figure 8. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. Hamlin PA, Satram-Hoang S, Reyes C, Hoang KQ, Guduru SR, Skettino S. Oncologist. All authors reviewed the paper, and approved the final manuscript. As a graphic expression of a mathematical model, the nomogram helps to determine the possibility of clinical event by combing biological and clinical variables. Some limitations due to information availability in the SEER database should be noticed when interpreting our findings. Am J Epidemiol. Second Primary Malignancies in Mantle Cell Lymphoma: A US Population-based Study. Blood. Extranodal diffuse large B-cell lymphoma incidence (1973–2015) and incidence-based mortality (1988–2015): the SEER-9 registry database. The 5-year survival rates have improved dramatically from the 1970s to 2010s (44.15 vs. 63.7%), and the most obvious increase occurred in patients with primary site in the head/neck. The data from RICOVER-60 trial showed that elderly females who gained the best beneficial effects from rituximab had a statistically significant slower clearance of rituximab, which brought about longer exposure time and higher serum levels in relation to an age-dependent decrease in clearance of rituximab in females (32). Auris Nasus Larynx. Cancer Epidemiol Biomark Prevent. | Acknowledgements. The DLBCL is coded as a second primary for several reasons: to determine the incidence of follicular lymphomas transforming to DLBCL; survival time can be calculated for the diagnosis of the more aggressive DLBCL; death will be attributed to the DLBCL (for mortality statistics) and not the follicular lymphoma. The incremental cost of treatment failure was $14,174 per month, driven by higher initial treatment costs ($13,866 vs $4,754) and the need for secondary and/or palliative care ($5,062). Dulac: Celgene Corporation: Employment. Figure 5. The overall mortality trend of extranodal DLBCL began to decline in 1993, which was 10 years earlier than incidence, indicating that the main reason for the decline of extranodal DLBCL mortality is the improvement of survival rate. Zhang ZY, Luo QF, Yin XW, Dai ZL, Basnet S, Ge HY. 2011; Abramson et al. Impact Factor 4.848 | CiteScore 3.5More on impact ›, Thomas Jefferson University, United States, Department of Hematology, Sixth Medical Center of PLA General Hospital, China. National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error. Step 3: Click on the 2010 HEMATOPOIETIC CODING MANUAL (PDF) button. Both the incidence and incidence-based mortality of early stage patients showed an initial significant increase and then turn to decrease. (D) Overall survival in Respiratory system; (E) Overall survival in Liver/pancreas; (F) Overall survival in Breast tissue; (G) Overall survival in Genitourinary tract; (H) Overall survival in Other. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Kaplan–Meier's analysis for extranodal DLBCL. | doi: 10.1080/10428190701809156, 31. Trends of annual incidence of extranodal DLBCL according to gender. Hum Reprod Update. Get the latest research from NIH: https://www.nih.gov/coronavirus. One QoL study was identified, a UK study that reported statistically significant differences by disease state using multiple QoL instruments. Trends in extranodal diffuse large B-cell lymphoma incidence rates (1973–2015): the SEER-9 registry database. Graph shows increasing survival from the 1970s to 2010s. History of autoimmune conditions and lymphoma prognosis. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, et al. … Publicly available datasets were analyzed in this study. doi: 10.1111/bjh.15444, 9. Gastric MALT lymphoma: from aetiology to treatment. Trends of incidence and incidence-based mortality by tumor characteristics were described in Tables 2, 3, respectively.